Jan 14, 2025 · COPD among leading US causes of death, report says. Lower respiratory diseases including chronic obstructive pulmonary disease (COPD) were the sixth leading cause of death in the U.S. in 2022, accounting for 4.5% of all deaths registered that year.

Urine test may predict COPD exacerbations 1 week in advance. A urine test developed in a dipstick format by Global Access Diagnostics helped not only distinguish between stable and exacerbation states among chronic obstructive pulmonary disease (COPD) patients but also was able to predict exacerbations a week in advance.

Nov 25, 2024 · Assessing inflammation with vitamin B supplement. The University of Copenhagen launched a single-center trial (NCT04990869) at the Respiratory Research Unit at Bispebjerg Hospital in Copenhagen to test nicotinamide riboside against a placebo for its potential as a COPD treatment. The study included 40 adults, mean age 71.9, who had COPD, a history of heavy smoking, and low numbers of ...

Jan 27, 2025 · That’s according to a report, “Deaths: Leading Causes for 2022,” released by the U.S. Centers for Disease Control and Prevention.In 2021, COPD was the fourth leading cause of death worldwide, according to the World Health Organization. “COPD affects millions of people in the United States and worldwide,” Jean Wright, MD, CEO of the COPD Foundation, said in a foundation press release.

Recent Posts. The importance of choosing the right healthcare team December 17, 2024; Urine test may predict COPD exacerbations 1 week in advance December 9, 2024; Lung inflammation in COPD is reduced with a form of vitamin B3 November 25, 2024; Nature offers me a way of looking at smoking and COPD November 19, 2024; A story of COPD, vertigo, and a Jamaican ‘coal miner’ November 6, 2024

Jun 3, 2024 · Clinical trials of Dupixent for COPD. The applications are supported by two Phase 3 trials, BOREAS (NCT03930732) and NOTUS (NCT04456673), each involving more than 900 current or former smokers with COPD.All had signs of type 2 inflammation and uncontrolled disease despite using standard inhaled therapies, which …

Mar 18, 2024 · The THARROS study (NCT06283966) is expected to enroll up to 5,000 COPD patients, ages 40 to 80, with a risk of cardiopulmonary complications at more than 650 centers in the U.S., Canada, and countries in Europe, South America, and Asia.. Participants will be randomly assigned to receive either Breztri Aerosphere or to AstraZeneca’s dual-combination Bevespi Aerosphere (glycopyrronium ...

Dec 4, 2023 · Dupixent use also resulted in better lung function for these COPD patients, per an interim analysis of the NOTUS study (NCT04456673), which is expected to conclude in 2024.. The positive findings were robust enough for them to be considered the result of a main analysis, according to the therapy’s developers Sanofi and Regeneron Pharmaceuticals.The companies expect to present detailed trial ...

Dec 9, 2024 · Developing a test like ‘a personal weather forecast of an impending flare-up’ COPD occurs when long-lasting inflammation damages the airways, causing symptoms such as shortness of breath, persistent cough, and recurrent infections. Exacerbations, or flare-ups, are the “principal driver of poor health status, [hospitalizations], mortality and healthcare costs,” the researchers wrote.

Jun 17, 2024 · That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which confirmed previous findings in the similarly designed Phase 3 BOREAS study (NCT03930732). “In my more than 20 years of practice, there have been limited advancements for patients struggling with the debilitating effects of uncontrolled COPD, and too many patients experience a vicious cycle of ...